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ABSTRACT
Background Gastro-protective agents (GPA) are
co-prescribed with non-steroidal anti-inflammatory drugs
(NSAID) to lower the risk of upper gastrointestinal (UGI)
events. It is unknown to what extent the protective
effect is influenced by therapy adherence.
Aim To study the association between GPA adherence
and UGI events among non-selective (ns) NSAID users.
Methods The General Practice Research Database (UK
1998e2008), the Integrated Primary Care Information
database (the Netherlands 1996e2007) and the Health
Search/CSD Longitudinal Patient Database (Italy
2000e2007) were used. A nested case-control design
was employed within a cohort of nsNSAID users aged
$50 years, who also used a GPA. UGI event cases (UGI
bleeding and/or symptomatic ulcer with/without
obstruction/perforation) were matched to event-free
members of the cohort for age, sex, database and
calendar time. Adherence to GPA was calculated as the
proportion of nsNSAID treatment days covered by a GPA
prescription. Adjusted OR with 95% CI were calculated.
Results The cohort consisted of 618 684 NSAID users,
generating 1 107 266 nsNSAID episodes. Of these, 117
307 (10.6%) were (partly) covered by GPA, 4.9% of
which with a GPA coverage <20% (non-adherence), and
68.1% with a GPA coverage >80% (full adherence). 339
patients experienced an event. Among non-adherers, the
OR was 2.39 (95% CI 1.66 to 3.44) for all UGI events and
1.89 (95% CI 1.09 to 3.28) for UGI bleeding alone,
compared to full adherers.
Conclusions The risk of UGI events was significantly
higher in nsNSAID users with GPA non-adherence. This
underlines the importance of strategies to improve GPA
adherence.
Non-steroidal anti-inflammatory drugs (NSAID)
have analgesic and anti-inflammatory properties,
and are indicated mainly for pain management in
musculoskeletal injury, osteoarthritis and rheuma-
toid arthritis. The use of NSAID may lead to upper
gastrointestinal (UGI) symptoms such as dyspepsia,
and to more severe events such as gastroduodenal
ulcers or UGI bleeding. The incidence of such clini-
cally significant UGI events during NSAID use has
been estimated at 1e2.5/100 person-years1 2 and is
associated with substantial mortality.3 Non-selec-
tive (ns) NSAID inhibit the cyclooxygenase 1
enzyme more strongly than cyclooxygenase 2 selec-
tive inhibitors.4 As cyclooxygenase 1 is involved in
gastroprotection, nsNSAID are believed to increase
the risk of UGI events to a higher degree than
cyclooxygenase 2 inhibitors.5
To prevent UGI events during nsNSAID use,
evidence-based guidelines recommend the concom-
itant use of gastroprotective agents (GPA),6 mostly
in nsNSAID users with one or more risk factors.
The guidelines differ slightly in their definition of
risk factors, but most consider advanced age, the
history of a UGI event and the use of antiplatelet
agents, anticoagulants or corticosteroids as risk
factors.7e9 Some guidelines also mention other
factors, including the use of selective serotonin
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Significance of this study
What is already known about this subject?
< The use of non-selective non-steroidal anti-
inflammatory drugs (nsNSAID) may lead to
upper gastrointestinal (UGI) ulcers and bleeding.
< Gastroprotective agents (GPA) are recom-
mended to reduce the risk of nsNSAID-related
UGI events in patients with risk factors for
developing nsNSAID-related UGI events.
< Previous studies have suggested that the preven-
tive effect of GPA during nsNSAID use is
compromised by suboptimal adherence, but the
magnitude of this effect remains to be determined.
What are the new findings?
< GPA adherence differs between European
countries.
< The risk of UGI bleeding and symptomatic UGI
ulcers was increased in patients with low GPA
adherence.
< The association between low GPA adherence
and UGI events was present in patients with and
without risk factors.
How might they impact on clinical practice in
the foreseeable future?
< The results strongly highlight the importance of
GPA adherence during nsNSAID use.
< Increasing adherence to GPA may reduce the
risk of nsNSAID-related UGI events.
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reuptake inhibitors, infection with Helicobacter pylori or the
presence of heart failure.7e9
The actual concomitant use of GPA with nsNSAID can be
problematical for two reasons: suboptimal prescription by the
physician and suboptimal use by the patient. Although the
situation has recently been improving,10 even recent observa-
tional studies estimated that 67e90% of the nsNSAID users
with at least one risk factor did not receive GPA as recom-
mended.11e15 Two other studies showed that 25e50% of the
patients did not use their GPA on a daily basis.16 17
Lack of adherence to concomitant GPA was shown to be
associated with an increased risk of nsNSAID-induced UGI
events, but the studies concerned were limited by lack of power,
especially to detect an effect on the risk of UGI bleeding.16 18 To
investigate the extent of suboptimal GPA adherence during
nsNSAID use and the consequences thereof, a caseecontrol
study nested within a cohort of nsNSAID plus GPA users aged
50 years or older drawn from three similar European population-
based primary care research databases was conducted.
Combining data from comparable medical record databases in
different countries (UK, The Netherlands and Italy) enabled
increased statistical power and expanded the inclusion to a wide
variety of NSAID, resulting in increased generalisability.
METHODS
Data sources
Data for this study were obtained from three similar population-
based primary care registries from the UK, The Netherlands and
Italy. In the British, Dutch and Italian national healthcare
systems, all citizens are registered with a primary care practice,
which records all relevant medical information. Data recorded
include demographics, symptoms and diagnoses, laboratory test
results, drug prescriptions, specialist referrals, clinical diagnoses
from outpatient visits and hospital discharge summaries. The
databases comply with European Union guidelines on the use of
medical data for medical research and have been demonstrated
to be valid for pharmacoepidemiology research. In the EUeADR
project it was shown that primary care databases from Italy,
The Netherlands and the UK were very similar in terms of UGI
event rates.19 The databases are briefly described below.
General practice research database (1998e2008)
The general practice research database (GPRD) is a dynamic
longitudinal primary care research database from the UK that
was established in 1987. Currently, there are more than 500
active practices and 4.4 million active patients who are demo-
graphically representative of the UK population. Symptoms and
diagnoses are recorded using the thesaurus of clinical terms used
in the UK (READ codes) and information on drug prescriptions
is coded using the Multilex product dictionary and British
National Formulary codes. When available, we requested addi-
tional information on hospitalisations from hospital episode
statistics data including procedures coded according to the Office
of Population, Censuses and Surveys: Classification of Inter-
ventions and Procedures, 4th revision and diagnoses coded
according to the International Classification of Diseases, 10th
revision.
Integrated primary care information database (1996e2007)
The integrated primary care information (IPCI) database is
a dynamic longitudinal primary care research database from The
Netherlands that was set up in 1992. The database covers
approximately 800 000 patients from 150 active practices.
Symptoms and diagnoses are recorded using the international
classification for primary care20 and free text; drug prescriptions
are coded according to the anatomical therapeutic chemical
(ATC)21 classification.
Health search/CSD longitudinal patient database (2000e2007)
The health search/CSD longitudinal patient database (HSD) is
a dynamic longitudinal primary care database from Italy that
was established in 1998. The HSD currently contains data from
over 900 general practitioners and covers approximately 1.6
million patients.22 Symptoms and diagnoses are recorded using
the International Classification of Diseases, 9th Revision, Clin-
ical Modification. Information on drug prescriptions is coded
according to the ATC classification.
The protocol of the present study was approved by the
Scientific and ethical advisory board of each database.
Source population
For each database, patients were eligible for inclusion in the
source population from the start of the study period, at 50 years
of age or the date on which at least 1 year of valid enrollment
data were obtained (whichever was latest). Eligibility ended at
death, last data supply, transferring out of the practice, or end of
the study period, whichever came first.
Study cohorts and exposure assessment
Two types of exposure cohorts were created: (1) NSAID cohort
(nsNSAID plus cyclooxygenase 2 inhibitors) and (2) nsNSAID
plus GPA subcohort, which was selected from the NSAID
cohort. For each database, the NSAID cohort included all
patients from the source population who received at least one
NSAID prescription (ATC codes (or equivalent British National
Formulary code) M01AAeM01AX, or ATC codes N02BA01,
N02BA15 or N02BA51 at a dose >325 mg) during the eligibility
period, and who did not receive any NSAID prescription during
the 6 months previously. All identified new users of NSAID were
followed from the start of NSAID therapy to the end of the
eligibility period or the occurrence of the study outcome
(whichever came earliest). Patients with a neoplasm of the
gastrointestinal tract, alcohol abuse, chronic liver disease,
Crohn’s disease, ulcerative colitis or a coagulopathy recorded
before or during follow-up were excluded from the cohort.
Within the NSAID cohort, episodes of NSAID use were
defined as consecutive NSAID prescriptions with gaps not
exceeding the duration of the previous NSAID prescription. For
each prescription, duration was calculated by dividing the
prescribed quantity by daily dose regimen (GPRD/IPCI) or the
indication-specific defined daily dose (HSD). The end of an
episode was defined as the end of the last NSAID prescription
within that episode or the end of follow-up (whichever came
earliest). There was no lower limit for consecutive NSAID use,
in order to increase generalisability and to avoid the exclusion of
events that occured with a first prescription. Patients could have
more than one episode of NSAID use during follow-up, but
eligible episodes were only those that had at least a 180-day
NSAID-free period before the start of the episode.
From the NSAID cohort we selected the nsNSAID plus GPA
subcohort, which comprised all nsNSAID users who received
GPA for at least 1 day during an eligible nsNSAID episode. The
beginning of the nsNSAID plus GPA episode was based on the
beginning of the nsNSAID prescription; the GPA could have
started earlier, on the same day or later during the episode.
Patients could have more than one eligible episode of nsNSAID
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plus GPA use and re-enter the cohort. All episodes that included
Arthrotec (fixed combination of diclofenac with misoprostol;
ATC code M01AB55) or cyclooxygenase 2 inhibitors (ATC code
M01AH) or a combination of products (combination of
nsNSAID, cyclooxygenase 2 inhibitors and/or Artrotec) were
excluded (figure 1).
In this cohort, follow-up started at the beginning of the
nsNSAID plus GPA episode and ended 60 days after the end of
the last nsNSAID prescription in that episode (or the end of
eligibility if earlier). This carry-over period was added because
the nsNSAID-associated elevated risk of UGI events is believed
to return to baseline approximately 2 months after stopping
treatment.23
Among GPA we included proton pump inhibitors (PPI; ATC
codes A02BC and A02BD), high-dosed histamine-2 receptor
antagonist (H2RA; ATC code A02BA)6 and misoprostol (ATC
code A02BB01). The duration of GPAwas calculated as described
above for NSAID.
Adherence calculation
Within the nsNSAID plus GPA cohort, each particular
nsNSAID day within an eligible episode was classified as being
or as not being covered with a GPA prescription. Adherence
estimates were created on the basis of the percentage of
nsNSAID days covered (PDC) by a GPA. Adherence was
expressed as both a continuous and a categorical variable: (1)
non-adherence (PDC <20%); (2) moderate adherence (PDC
20e80%); and (3) full adherence (PDC >80%). This catego-
risation separates extremes and is based on previous studies on
treatment adherence.18 24
Case and control definition
Cases were members from the nsNSAID plus GPA cohort who
had an UGI event, which was defined as UGI bleeding and/or
symptomatic UGI ulcer with or without perforation or
obstruction, during follow-up. UGI events were identified by
a sensitive electronic search and were subsequently manually
(IPCI) or electronically (GPRD, HSD) validated considering all
relevant information available in each database (ie, histology
reports, specialist letters, endoscopy results, clinical notes as
free text). Different systems for coding and recording clinical
details prompted us to consider different search and validation
algorithms for each database. In general, cases were classified as
definite if: (1) an endoscopy record confirming the UGI
event was available; (2) the event was mentioned together with
the exact location (eg, ‘acute duodenal ulcer with haemor-
rhage’); (3) there was a recording of a hospital admission
or anaemia within 1 month of the event. Cases were classified
as probable if the occurrence of a UGI event was mentioned,
but was unconfirmed or non-specific (eg, ‘blood in vomit’).
Angiodysplasias, oesophageal varices and MalloryeWeiss
syndrome were excluded as a case. The index date was defined
as the start of the sign/symptom leading to the diagnosis of
the UGI event, if present; otherwise it was defined as the date
of diagnosis.
To each case we matched all eligible persons from the
nsNSAID plus GPA cohort who were at the index date of the
corresponding case: alive, at risk of an nsNSAID-related UGI
event (ie, being in follow-up), of similar age (63 years) and the
same sex, and were present in the same database as the case.
This matching method samples from person time rather than
UK (GPRD)
Source population 
N=4 727 334
New NSAID users 
N=384 649 
Total follow-up=3 233 557 py
NSAID user episodes 
N=1 313 314 
Eligible NSAID user episodes 
N=748 901 
<180 days NSAID-free period 
prior to start episode: N=564 413 
Coxib episodes: 52 698 
Arthrotec episodes: 360430 
Combination episodes: 12 158 
Eligible nsNSAID user episodes 
N=647 615 
Eligible nsNSAID+GPA episodes 
N=74 813 
generated in 59 031 patients 
nsNSAID episodes without GPA: 
572 802 
NL (IPCI)
Source population 
N=154 518
New NSAID users
N=55 005 
Total follow-up=197 20 py
NSAID user episodes
N=151 841 
Eligible NSAID user episodes
N=97 675 
<180 days NSAID-free period 
prior to start episode: N=54 166 
Coxib episodes: 7201 
Arthrotec episodes: 10 559 
Combination episodes: 1062 
Eligible nsNSAID user episodes 
N=78 854 
Eligible nsNSAID+GPA episodes
N=6162 
generated in 5045 patients 
nsNSAID episodes without GPA: 
72 691 
IT (HSD)
Source population 
N=370 013
New NSAID users
N=179 030 
Total follow-up=814 625 py
NSAID user episodes
N=875 046 
Eligible NSAID user episodes
N=433 836 
<180 days NSAID-free period 
prior to start episode: N=441 210 
Coxib episodes: 39 041 
Arthrotec episodes: 3915 
Combination episodes: 10 082 
Eligible nsNSAID user episodes 
N=380 798 
Patients 
Episodes 
NSAID cohort 
nsNSAID+GPA cohort 
Eligible nsNSAID+GPA episodes
N=36 332 
generated in 27 206 patients 
nsNSAID episodes without GPA: 
344 466 
Figure 1 Cohort selection by database. GPA, gastroprotective agent; GPRD, general practice research database; HSD, health search/CSD longitudinal
patient database; IPCI, integrated primary care information; IT, Italy; NSAID, non-steroidal anti-inflammatory drug; nsNSAID, non-selective non-steroidal
anti-inflammatory drug; NL, The Netherlands.
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persons and the controls should be regarded as person moments,
similarly to a cohort approach. Adherence was calculated for the
most recent episode of nsNSAID use (with censoring at the
event) before the event.
Covariates
As covariates we evaluated the presence of risk factors for
NSAID-related UGI events as commonly described in guidelines
on the prevention of NSAID-related UGI events:7e9 (1) age
65 years or greater; (2) history of UGI event; (3) concomitant use
of antiplatelets; (4) concomitant use of anticoagulants; or (5)
concomitant use of systemic steroids greater than 5 mg daily. In
the nested caseecontrol analysis, covariates were assessed before
the index date. Concomitant use was defined as drug use over-
lapping the index date.
We additionally evaluated the presence of dyspepsia/gastro-
oesophageal reflux in the year before the nsNSAID episode,
(history of) smoking, presence of heart failure or diabetes, the
concomitant use of serotonin reuptake inhibitors, spirono-
lactone25 26 or calciumantagonists, calendar year, the length of the
NSAID episode and the density of NSAID use (number of NSAID
prescription days divided by episode length) within the episode.
Statistical analyses
Baseline characteristics of the NSAID and nsNSAID plus GPA
cohort were described by database. The database-specific and
pooled crude incidence rates of UGI events within the NSAID
cohort were estimated together with 95% CI based on the
Poisson distribution, and expressed per 1000 NSAID user-years.
Events that occurred during or within 60 days after an eligible
NSAID episode were counted. In a subanalysis we calculated
separately the incidence rate of UGI bleeding. Exposure time was
censored at the occurrence of the outcome of interest.
GPA adherence in the nsNSAID plus GPA cohort was
described by database and by the presence of the five major risk
factors as described under ‘Covariates’. To estimate the risk of
nsNSAID-related UGI events and UGI bleeding according to
GPA adherence we calculated pooled adjusted matched OR with
95% CI through conditional logistic regression analyses, while
adjusting for all covariates that changed the estimated risk in
any of the exposure categories by more than 10%. Statistical
heterogeneity across databases was tested by using a Cochran’s
Q statistic, and no significant results were found.
The analyses were stratified by type of first used nsNSAID,
duration of nsNSAID episode and the presence of the major risk
factors (assessed at the index date). To test the robustness of our
findings, sensitivity analyses were performed by restricting the
analysis to definite cases only, to cases and controls using
nsNSAID for at least 30 or 60 days or to only the first nsNSAID
episode per patient.
We calculated the number needed to treat (NNT) within the
nsNSAID plus GPA cohort based on the risk estimate in patients
with full adherence compared with patients with non-adherence,
and the UGI event rate in the non-adherent group. The NNT
expresses the number of nsNSAID years during which patients
need to be fully adherent to the GPA to prevent one UGI event.27
This calculation was done separately for patients with no UGI
risk factors and patients with at least one UGI risk factor.
All analyses were performed using SPSS 15.0 for Windows. A
two-sided p-value of less than 0.05 was considered to be
statistically significant.
RESULTS
NSAID cohort
Within the source population of 5 251 865 patients, we identified
618 684 patients who newly started on NSAID at least once
Table 1 Cohort characteristics for the NSAID cohort (at cohort entry) and for the nsNSAID plus GPA cohort (at start of each eligible episode) by
database
NSAID cohort nsNSAID plus GPA cohort
UK NL IT UK NL IT
n[384 649 n[55 005 n[179 030 n[74 813 n[6162 n[36 332
n (%) n (%) n (%) n (%) n (%) n (%)
Age (mean6SD) 64.8610.6 63.4610.7 64.6610.7 68.9610.6 65.4610.9 68.6610.5
Male 157 881 (41.0) 23 897 (42.7) 74 571 (41.7) 28 047 (37.5) 2257 (36.6) 14 397 (39.6)
Individual UGI risk factors
Age $65 years 177 975 (46.3) 22 845 (40.8) 83 174 (46.5) 45 807 (61.2) 2954 (47.9) 22 024 (60.6)
Previous UGI event 16 953 (4.4) 1134 (2.0) 7056 (3.9) 9040 (12.1) 385 (6.2) 3704 (10.2)
Use of antiplatelets 49 782 (12.9) 1682 (3.0) 13 629 (7.6) 20 043 (26.8) 853 (13.8) 6034 (16.6)
Use of anticoagulants 2809 (0.7) 334 (0.6) 1274 (0.7) 1191 (1.6) 148 (2.4) 553 (1.5)
Use of systemic steroids 4169 (1.1) 260 (0.5) 3797 (2.1) 2539 (3.4) 117 (1.9) 2302 (6.3)
No of UGI risk factors*
0 186 188 (48.4) 32 029 (57.2) 86 331 (48.2) 21 080 (28.2) 2689 (43.6) 10 582 (29.1)
1 149 015 (38.7) 21 805 (38.9) 77 198 (43.1) 31 947 (42.7) 2556 (41.5) 17 595 (48.4)
2 45 762 (11.9) 2083 (3.7) 14 785 (8.3) 18 820 (25.2) 852 (13.8) 7460 (20.5)
3 3589 (0.9) 92 (0.2) 702 (0.4) 2834 (3.8) 63 (1.0) 6,78 (1.9)
$4 95 (0.0) 2 (0.0) 14 (0.0) 132 (0.2) 2 (0.0) 17 (0.0)
Type of NSAID
nsNSAID 353 036 (91.8) 46 778 (85.0) 158 093 (88.3) 74 813 (100.0) 6162 (100.0) 36 332 (100.0)
Cyclooxygenase 2 inhibitors 18 261 (4.7) 3266 (5.9) 18 411 (10.3) Excluded Excluded Excluded
Arthrotec 12 581 (3.2) 4885 (8.9) 1725 (1.0) Excluded Excluded Excluded
Combinations 771 (0.2) 76 (0.1) 801 (0.5) Excluded Excluded Excluded
*Included in the count were previous UGI event (in any previous history), concomitant antiplatelet use, concomitant anticoagulant use, concomitant use of systemic steroids greater than 5 mg
daily and age greater than 65 years.
GPA, gastroprotective agent; IT, Italy; NL, The Netherlands; NSAID, non-steroidal anti-inflammatory drug; nsNSAID, non-selective non-steroidal anti-inflammatory drug; UGI, upper
gastrointestinal.
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during the eligibility period (figure 1). The mean eligibility time
per patient was 8.4 years in the UK, 3.6 years in The
Netherlands and 4.6 years in Italy.
Table 1 shows the characteristics of the NSAID cohort by
database. Most patients in the NSAID cohort started on
nsNSAID (n¼557 907; 90.2%). The most commonly prescribed
nsNSAID were ibuprofen in the UK (69.8%), diclofenac in The
Netherlands (38.6%) and nimesulide in Italy (28.5%). The mean
age in the NSAID cohort was 64.6610.7 years and 41.4% were
men. Most patients had no (n¼310 028; 50.1%) or one
(n¼259 668; 42.0%) risk factor for NSAID-induced UGI bleeding
or ulcer. The most common risk factor was age of 65 years or
greater (n¼283 994; 45.9%).
During follow-up of the NSAID cohort, 2 340 201 NSAID user
episodes were counted, 1 280 412 of which were eligible (ie, had
at least a 180-day NSAID-free period before the start of the
episode) (figure 1). The mean duration per NSAID episode was
27.5671.5 days.
Incidence rates
In total, we identified 2056 patients with a UGI event (1182
UGI bleedings and 874 symptomatic ulcers), which occurred
during or within 60 days of an eligible NSAID episode. The
incidence rates are described in table 2. The incidence rate was
6.7 (95% CI 6.4 to 7.0) per 1000 NSAID user-years for UGI
events and 3.8 (95% CI 3.5 to 4.1) per 1000 NSAID user-years for
UGI bleedings.
Of all UGI events that occurred during an NSAID episode or
within 60 days thereafter, 413 (20.1%) concerned an NSAID
episode with concomitant GPA. For UGI bleeding, this
Table 2 Incidence rates of UGI events during eligible NSAID episodes in the NSAID cohort
UGI events (UGI bleeding and ulcer) UGI bleeding
n NSAID user-years Incidence* (95% CI) n NSAID user-years Incidence* (95% CI)
Total 2056 306281.3 6.7 (6.4 to 7.0) 1182 307506.65 3.8 (3.5 to 4.1)
Age, years
50e65 598 152902.6 3.9 (3.6 to 4.2) 272 153361.87 1.8 (1.6 to 2.0)
65e75 595 87061.3 6.8 (6.3 to 7.4) 330 87490.86 3.8 (3.4 to 4.2)
>75 863 66317.5 13.0 (12.2 to 13.9) 580 66653.92 8.7 (8.0 to 9.4)
Gender
Male 967 120532.0 8.0 (7.5 to 8.5) 562 121092.25 4.6 (4.3 to 5.0)
Female 1089 185749.4 5.9 (5.5 to 6.2) 620 186414.40 3.3 (3.1 to 3.6)
Individual UGI risk factors
Age $65 years 1458 153378.7 9.5 (9.0 to 10.0) 910 154144.78 5.9 (5.5 to 6.3)
Previous UGI event 209 12041.2 17.4 (15.1 to 19.8) 128 13121.10 9.8 (8.2 to 11.6)
Use of antiplatelets 537 41557.8 12.9 (11.9 to 14.1) 350 41781.33 8.4 (7.5 to 9.3)
Use of anticoagulants 40 2652.0 15.1 (10.9 to 20.3) 32 2667.36 12.0 (8.4 to 16.7)
Use of systemic steroids 58 4894.9 11.9 (9.1 to 15.2) 38 4930.46 7.7 (5.5 to 10.5)
No of UGI risk factorsy
0 464 135939.0 3.4 (3.1 to 3.7) 203 135988.33 1.5 (1.3 to 1.7)
1 960 128922.1 7.5 (7.0 to 7.9) 552 129341.65 4.3 (3.9 to 4.6)
2 557 38727.9 14.4 (13.2 to 15.6) 378 39304.89 9.6 (8.7 to 10.6)
3 72 2624.0 27.4 (21.6 to 34.3) 46 2794.67 16.5 (12.2 to 21.8)
4 or more 3 67.3 44.6 (12.3 to 118.9) 3 75.99 39.5 (10.9 to 105.3)
Type of first NSAIDz
nsNSAID 1800 275695.0 6.5 (6.2 to 6.8) 1051 276703.0 3.8 (3.6 to 4.0)
Ibuprofen 721 121783.8 5.9 (5.5 to 6.4) 495 122052.4 4.1 (3.7 to 4.4)
Diclofenac 289 41418.3 7.0 (6.2 to 7.8) 159 41601.2 3.8 (3.3 to 4.5)
Naproxen 263 31191.9 8.4 (7.5 to 9.5) 182 31271.0 5.8 (5.0 to 6.7)
Nimesulide 129 26567.9 4.9 (4.1 to 5.8) 27 26739.8 1.0 (0.7 to 1.5)
Others/combinations 398 54733.1 7.3 (6.6 to 8.0) 188 55038.6 3.4 (3.0 to 3.9)
Cyclooxygenase 2 inhibitors 256 30586.3 8.4 (7.4 to 9.4) 131 30803.7 4.3 (3.6 to 5.0)
Celecoxib 99 13336.6 7.4 (6.1 to 9.0) 49 13434.8 3.7 (2.7 to 4.8)
Rofecoxib 115 12859.0 8.9 (7.4 to 10.7) 58 12933.0 4.5 (3.4 to 5.8)
Other/combinations 42 4390.7 9.6 (7.0 to 12.8) 24 4435.9 5.4 (3.6 to 7.9)
Origin of database
UK 1392 198581.1 7.0 (6.7 to 7.4) 927 199162.7 4.7 (4.4 to 5.0)
The Netherlands 128 19341.2 6.6 (5.5 to 7.8) 92 19372.5 4.8 (3.9 to 5.8)
Italy 536 883593.0 6.1 (5.6 to 6.6) 163 88971.5 1.8 (1.6 to 2.1)
No GPA 1643 266886.6 6.2 (5.9 to 6.5) 965 267479.42 3.6 (3.4 to 3.8)
With GPA 413 39394.7 10.5 (9.5 to 11.5) 217 40027.23 5.4 (4.7 to 6.2)
GPA adherence
PDC <20% 47 4125.7 11.4 (8.5 to 15.0) 19 4180.92 4.5 (2.8 to 7.0)
PDC 20e80% 120 11735.3 10.2 (8.5 to 12.2) 58 11909.43 4.9 (3.7 to 6.3)
PDC >80% 246 23533.81 10.5 (9.2 to 11.8) 140 23936.88 5.9 (4.9 to 6.9)
*Incidence per 1000 NSAID user-years.
yIncluded in the count were previous UGI event (in any previous history), concomitant antiplatelet use, concomitant anticoagulant use, concomitant use of systemic steroids greater than 5 mg
daily and age greater than 65 years.
zEpisodes with Arthrotec use or with a combination of nsNSAID with cyclooxygenase 2 inhibitors were excluded.
GPA, gastroprotective agent; NSAID, non-steroidal anti-inflammatory drug; nsNSAID, non-selective non-steroidal anti-inflammatory drug; PDC, percentage of NSAID days covered with GPA;
UGI, upper gastrointestinal.
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percentage was similar (18.4%, n¼217). The crude incidence
rates of UGI events and UGI bleeding were significantly higher
among GPA users than among non-GPA users (table 2). For UGI
events, the crude incidence rates among cyclooxygenase 2
inhibitor users were significantly higher compared with
nsNSAID users.
nsNSAID plus GPA cohort
After exclusion of episodes that included the use of cyclo-
oxygenase 2 inhibitors (n¼98 940) or Arthrotec (n¼50 904) or
a combination of products (n¼23 302), 1 107 266 eligible
nsNSAID episodes remained (figure 1). The mean number of
eligible nsNSAID episodes per patient was 1.9. The mean length
of the eligible nsNSAID episodes was 31.1 days (SD 73.5).
In 117 307 (10.6%) of the eligible nsNSAID episodes a GPA
was prescribed (UK 11.6%; The Netherlands 7.8%, Italy 9.5%)
and these episodes were the basis for the nsNSAID plus GPA
cohort, comprising 91 282 patients (figure 1). The characteristics
of this cohort are described in table 1.
Adherence to GPA in the eligible nsNSAID episodes is
described in table 3. Overall, mean adherence was 0.8160.28
(UK 0.8360.27; The Netherlands 0.8860.24; Italy 0.7460.30),
and 79 869 patients (68.1%) (UK 71.8%; The Netherlands 80.5%;
Italy 58.3%) were fully adherent.
Nested caseecontrol study
In the nsNSAID plus GPA cohort 339 UGI events occurred
during follow-up, 187 of which were UGI bleeds. All patients
with a UGI event during follow-up were included as cases and
71 380 controls were matched. The characteristics of the cases
and controls at the index date are described in table 4.
The mean GPA adherence (PDC) of cases and controls was
0.7460.33 and 0.8260.28, respectively. The p value for the
Cochran’s Q statistic was 0.13, indicative of statistical homo-
geneity across databases. With every 10% decline in PDC, the risk
of a UGI event increased by 9% (95% CI 5% to 13%) (table 5).
NsNSAID users who were non-adherent to GPA had a 2.4-fold
increased risk of UGI events (95% CI 1.7 to 3.4) compared with
Table 3 GPA adherence during nsNSAID use (in nsNSAID plus GPA cohort)
GPA adherence (PDC)
<20% 20e80% >80%
n Mean PDCy (SD) n (%) n (%) n (%)
Total 117 307 0.81 (0.28) 5723 (4.9) 31 715 (27.0) 79 869 (68.1)
Age, years
50e65 4522 0.80 (0.28) 2350 (5.1) 12 776 (27.5) 31 396 (67.5)
65e75 35 973 0.81 (0.28) 1785 (5.0) 9658 (26.8) 24 530 (68.2)
>75 34 812 0.81 (0.27) 1588 (4.6) 9281 (26.7) 23 943 (68.8)
Gender
Male 44 701 0.81 (0.28) 2129 (4.8) 11 956 (26.7) 30 616 (68.5)
Female 72 606 0.81 (0.28) 3594 (5.0) 19 759 (27.2) 49 253 (67.8)
Individual UGI risk factors
Age $65 years 70 785 0.81 (0.28) 3373 (4.8) 18 939 (26.8) 48 473 (68.5)
Previous UGI event 13 129 0.84 (0.25) 447 (3.4) 3002 (22.9) 9680 (73.7)
Use of antiplatelets 26 930 0.83 (0.26) 1092 (4.1) 6355 (23.6) 19 483 (72.3)
Use of anticoagulants 1892 0.85 (0.25) 64 (3.4) 423 (22.4) 1405 (74.3)
Use of systemic steroids 4958 0.82 (0.27) 238 (4.8) 1280 (25.8) 3440 (69.4)
No of UGI risk factors*
0 34 351 0.79 (0.29) 1871 (5.4) 9869 (28.7) 22 611 (65.8)
1 52 098 0.80 (0.28) 2611 (5.0) 14 476 (27.8) 35 011 (67.2)
2 27 132 0.83 (0.27) 1122 (4.1) 6617 (24.4) 19 393 (71.5)
3 3575 0.86 (0.24) 117 (3.3) 723 (20.2) 2735 (76.5)
4 or more 151 0.89 (0.19) 2 (1.4) 30 (20.3) 119 (78.8)
Type of first NSAID
Ibuprofen 47 782 0.83 (0.26) 2070 (4.3) 11 251 (23.5) 34 461 (72.1)
Diclofenac 19 936 0.81 (0.28) 876 (4.4) 5452 (27.3) 13 608 (68.3)
Nimesulide 8784 0.73 (0.31) 654 (7.4) 3012 (34.3) 5118 (58.3)
Naproxen 14 253 0.83 (0.26) 550 (3.9) 3517 (24.7) 10 186 (71.5)
Others/combinations 26 552 0.77 (0.29) 1573 (5.9) 8483 (31.9) 16 496 (62.1)
Type of GPA
PPI 115 937 0.81 (0.28) 5645 (4.9) 31 286 (27.0) 79 006 (68.1)
H2RA 3 0.94 (0.10) 0 0 3 (100)
Misoprostol 999 0.76 (0.30) 51 (5.1) 313 (31.3) 635 (63.6)
Combination of GPA 371 0.76 (0.30) 27 (7.3) 116 (31.3) 228 (61.5)
Duration of episodey
<1 month 68 519 (58.4) 0.87 (0.24) 2086 (3.0) 13 659 (19.9) 52 774 (77.0)
1e6 months 43 843 (37.4) 0.73 (0.29) 2500 (5.7) 16 608 (37.9) 24 735 (56.4)
6e12 months 2599 (2.2) 0.65 (0.34) 473 (18.2) 826 (31.8) 1300 (50.0)
>12 months 2346 (2.0) 0.58 (0.38) 664 (28.3) 622 (26.5) 1060 (45.2)
*Included in the count were previous UGI event (in any previous history), concomitant antiplatelet use, concomitant anticoagulant use,
concomitant use of systemic steroids greater than 5 mg daily and age greater than 65 years.
yp for trend¼0.00.
GPA, gastroprotective agent; H2RA, histamine2 receptor antagonist; NSAID, non-steroidal anti-inflammatory drug; nsNSAID,
non-selective non-steroidal anti-inflammatory drug; PDC, percentage of NSAID days covered with GPA; PPI, proton pump inhibitor;
UGI, upper gastrointestinal.
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patients who were fully adherent. Upon restriction to definite
cases (n¼91), the association became stronger; with every 10%
decline in PDC, the risk of a UGI event increased by 16% (95% CI
9% to 25%). Upon restriction to patients with at least 30 (174
cases) or 60 (100 cases) days nsNSAID use during the episode or
to only the first nsNSAID episode per patient, the results were
similar to those of the original analysis (data not shown).
Analyses stratified by the type of nsNSAID, duration of
nsNSAID episode and the presence of risk factors are shown in
table 6. No major heterogeneity was observed, with the excep-
tion of patients with the concomitant use of anticoagulants or
corticosteroids, in whom the association between GPA adherence
and nsNSAID-related UGI events was no longer present.
When analysing the subset of UGI bleeding cases, the mean
adherence of the cases and the controls was 0.7860.30 and
0.8260.28, respectively. The p value for the Cochran’s Q
statistic was 0.62 for UGI bleeding, indicative of statistical
homogeneity across databases. With every 10% decline in PDC,
Table 4 Association between patient characteristics and UGI events (nested caseecontrol analysis in
nsNSAID plus GPA cohort)
Cases Controls
ORmatched (95% CI)
(n[339) (n[71 380)
N (%) N (%)
Age (mean6SD)* 71.6610.7 71.069.0 e
Male gender* 137 (40.4) 21631 (30.3) e
Type of first NSAIDy
Ibuprofen 89 (38.5) 25 768 (53.8) 1.0
Diclofenac 38 (16.5) 4421 (9.2) 1.87 (1.24 to 2.82)
Nimesulide 4 (1.7) 240 (0.5) 2.04 (0.60 to 6.90)
Naproxen 53 (22.9) 8772 (18.3) 2.00 (1.39 to 2.87)
Others/combinations 47 (20.3) 8683 (18.1) 1.32 (0.91 to 1.91)
UGI risk factors
Previous UGI event 69 (20.4) 6340 (8.9) 2.19 (1.67 to 2.87)
Use of antiplatelets 92 (27.1) 18 924 (26.5) 1.04 (0.81 to 1.32)
Use of anticoagulants 16 (4.7) 1228 (1.7) 2.79 (1.68 to 4.63)
Use of systemic corticosteroids 23 (6.8) 2861 (4.0) 1.67 (1.09 to 2.55)
Dyspepsia/reflux before NSAID start 21 (6.2) 3335 (4.7) 1.24 (0.80 to 1.94)
Smoking 123 (36.3) 28 423 (39.8) 0.94 (0.74 to 1.18)
Chronic heart failure 32 (9.4) 3132 (4.4) 1.71 (1.17 to 2.50)
Diabetes mellitus 58 (17.1) 10 280 (14.4) 1.20 (0.90 to 1.59)
Use of SSRI 37 (10.9) 5053 (7.1) 1.79 (1.27 to 2.54)
Use of spironolactone 2 (0.6) 616 (0.9) 0.61 (0.16 to 2.62)
Use of calcium antagonists 57 (16.8) 11 879 (16.6) 1.11 (0.83 to 1.48)
No of UGI risk factorsz
0 180 (53.1) 45 162 (63.3) 1.0
1 124 (36.6) 23 214 (32.5) 1.30 (1.03 to 1.65)
2 29 (8.6) 2874 (4.0) 2.29 (1.53 to 3.42)
3 6 (1.8) 129 (0.2) 10.39 (4.50 to 24.00)
4 0 1 (0.0) e
*Matching variables.
yAdjusted for dose. Patients were only included when dose was available (67.7%).
zIncluded in the count were previous UGI event (in any previous history), concomitant antiplatelet use, concomitant anticoagulant use
and concomitant use of systemic steroids greater than 5 mg daily. Excluding age greater than 65 years because age was a matching
variable. p for trend was 0.00.
GPA, gastroprotective agent; NSAID, non-steroidal anti-inflammatory drug; nsNSAID, non-selective non-steroidal anti-inflammatory
drug; SSRI, selective serotonin reuptake inhibitor; UGI, upper gastrointestinal.
Table 5 Association between adherence to gastroprotective agents during nsNSAID use and the risk of UGI events
Cases Controls ORmatched (95% CI) ORadjusted* (95% CI) p for trend
UGI events (UGI bleeding and ulcer)
Continuous: with every 10% decline in adherence 339 71 380 1.08 (1.04 to 1.12) 1.09 (1.05 to 1.13)
Categorical: 0.00
Adherence PDC >0.8 205 (60.5) 50 309 (70.5) 1.00 1.00
Adherence PDC 0.2e0.8 94 (27.7) 16 808 (23.5) 1.31 (1.02 to 1.67) 1.35 (1.05 to 1.73)
Adherence PDC <0.2 40 (11.8) 4263 (6) 2.15 (1.53 to 3.03) 2.39 (1.66 to 3.44)
UGI bleeding
Continuous: with every 10% decline in adherence 187 39571 1.04 (0.99 to 1.10) 1.06 (1.01 to 1.12)
Categorical 0.02
Adherence PDC >0.8 120 (64.2) 28 160 (71.2) 1.00 1.00
Adherence PDC 0.2e0.8 51 (27.3) 9091 (23) 1.26 (0.91 to 1.75) 1.30 (0.93 to 1.82)
Adherence PDC <0.2 16 (8.6) 2320 (5.9) 1.56 (0.93 to 2.64) 1.89 (1.09 to 3.28)
*Adjusted for length of NSAID episode, density of NSAID use within episode.
GPA, gastroprotective agent; NSAID, non-steroidal anti-inflammatory drug; nsNSAID, non-selective non-steroidal anti-inflammatory drug; PDC, percentage of NSAID days covered with GPA;
UGI, upper gastrointestinal.
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the risk of developing a UGI bleed increased by 6% (95% CI 1%
to 12%) (table 5). NsNSAID users who were non-adherent to
their GPA had a 1.9-fold increased risk of UGI bleeding (95% CI
1.1 to 3.3) compared with patients who were fully adherent
(table 5).
For calculation of the NNT, we calculated the nsNSAID-
related UGI event rate in non-adherent patients with no UGI
risk factor and with at least one UGI risk factor, being 7.7/1000
nsNSAID user-years (95% CI 3.8 to 14.0) and 18.9/1000
nsNSAID user-years (95% CI 3.7 to 25.5), respectively. In the
patients with no risk factors, patients with full adherence were
at a risk of 0.52 (95% CI 0.22 to 1.26) of developing a UGI event
compared with non-adherers. In the patients with at least one
risk factor, patients with full adherence were at a risk of 0.44
(95% CI 0.29 to 0.67) compared with non-adherers. Based on
these numbers, we calculated that for patients with no risk
factors, 274 nsNSAID user-years with GPA non-adherence
needed to be covered with full GPA adherence to prevent one
nsNSAID-related UGI event. For patients with at least one risk
factor, this was 96 nsNSAID user-years.
DISCUSSION
This large, population-based, multidatabase study shows that,
during nsNSAID use, non-adherence to GPA is associated with
a 2.4-fold increased risk of UGI bleeding and ulcers and a 1.9-fold
increased risk of UGI bleeding alone. With every 10% decrease in
GPA adherence, the risk increased by 9% for UGI bleeding and
ulcers and 6% for UGI bleeding alone. From the stratified anal-
ysis, it appears that full GPA adherence is important in both
nsNSAID users with risk factors for developing a UGI event and
nsNSAID users without any risk factor.
The results of this study are in line with two previous
observational studies, one from USA16 and one from Europe,18
which also showed an increased risk of UGI events associated
with low GPA adherence. As a result of the low use of GPA and
the relatively rare incidence of serious UGI events, the impact of
both studies was limited because of the small number of exposed
cases. In the present study we were able to include more than
300 exposed cases as we combined together three large primary
care databases. This allowed the conduction of several subanal-
yses. Randomised controlled trials on the subject are not avail-
able. This is understandable as in randomised controlled trials
adherence to the study drug is often well controlled. To study
the effects of drug adherence, real-world variability of use is
needed.
In our study the overall incidence of UGI events was 6.7/1000
NSAID user-years. The incidence was higher among patients
using GPA compared with patients who did not. This can be
explained by channelling, ie, patients who are at higher risk of
UGI events are more likely to be prescribed GPA or cyclo-
oxygenase 2 inhibitors. To minimise channelling bias, we created
the nsNSAID plus GPA cohort, excluding non-GPA users and
cyclooxygenase 2 inhibitor users. Nevertheless, in nsNSAID plus
GPA users only, it is conceivable that patients who are at higher
risk of developing UGI events will be more adherent to their
GPA. This is confirmed by the high crude incidence rate among
full adherers compared with patients who were moderately
adherent.
Table 6 Risk of UGI events with every 10% decline in GPA adherence during nsNSAID use: stratified
analyses
Cases Controls ORmatched (95% CI) ORadjusted* (95% CI)
Original 339 71 380 1.08 (1.04 to 1.12) 1.09 (1.05 to 1.13)
Type of first NSAIDy
Ibuprofen 89 25 768 1.02 (0.94 to 1.11) 1.04 (0.95 to 1.13)
Diclofenac 38 4421 1.20 (1.08 to 1.33) 1.19 (1.06 to 1.33)
Nimesulide 4 240 1.08 (0.71 to 1.63) 1.05 (0.66 to 1.69)
Naproxen 53 8772 1.08 (0.98 to 1.19) 1.10 (0.99 to 1.22)
Others/combinations 47 8683 1.11 (1.01 to 1.21) 1.15 (1.05 to 1.27)
Duration of NSAID episodez
<1 month 162 33 556 1.09 (1.02 to 1.16) 1.09 (1.02 to 1.16)
1e6 months 126 26 612 1.07 (1.00 to 1.14) 1.06 (1.00 to 1.13)
6e12 months 20 4440 1.17 (1.01 to 1.35) 1.20 (1.03 to 1.41)
>12 months 31 6772 1.07 (0.97 to 1.18) 1.07 (0.97 to 1.17)
Age, years
50e65 95 19 047 1.10 (1.03 to 1.17) 1.11 (1.04 to 1.19)
65e75 107 27 321 1.08 (1.01 to 1.15) 1.08 (1.01 to 1.15)
>75 137 25 012 1.07 (1.01 to 1.13) 1.08 (1.02 to 1.15)
Risk level
No UGI risk factors 65 14 246 1.11 (1.02 to 1.20) 1.12 (1.03 to 1.21)
$1 UGI risk factor 274 57 134 1.07 (1.03 to 1.11) 1.08 (1.03 to 1.12)
Previous UGI event
No 270 65 040 1.09 (1.05 to 1.13) 1.10 (1.06 to 1.15)
Yes 69 6340 1.07 (0.98 to 1.17) 1.07 (0.98 to 1.18)
Concomitant drug use
Antiplatelets 92 18 924 1.03 (0.96 to 1.11) 1.04 (0.81 to 1.32)
Anticoagulants 16 1228 0.98 (0.80 to 1.20) 0.95 (0.75 to 1.20)
Corticosteroids 23 2861 1.00 (0.85 to 1.18) 0.99 (0.83 to 1.17)
SSRI 37 5053 1.08 (0.96 to 1.22) 1.09 (0.96 to 1.23)
*Adjusted for length of NSAID episode, density of NSAID use within episode.
yAdditionally adjusted for dose. Patients were only included when dose was available (67.7%).
zOnly adjusted for density of NSAID use within episode.
GPA, gastroprotective agent; NSAID, non-steroidal anti-inflammatory drug; nsNSAID, non-selective non-steroidal anti-inflammatory
drug; SSRI, selective serotonin reuptake inhibitor; UGI, upper gastrointestinal.
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This study showed that mean GPA adherence is relatively
high (0.81). Although the number of nsNSAID users who
received a GPA prescription was lowest in The Netherlands,
adherence was highest in this country. In this study
(1996e2007), adherence in The Netherlands was slightly higher
(0.88) than in a previous study (0.82) from the same database
(1996e2002).17 Lowest adherence was found in Italy.
The strength of this study is the large amount of data from
three European countries. It describes real world prescription and
patient behaviour in the general population. As with all obser-
vational database studies, however, selection bias, information
bias and confounding need to be considered. Selection bias is
limited because in the cohort we included all eligible patients
available in the prospectively collected population-based data
from the three databases. The data in these databases is collected
for clinical use, irrespective of any research question.
Information bias includes misclassification of exposure and
misclassification of outcome. With regard to misclassification
of exposure, recall bias was avoided by using prescription
data but precise information on actual dispensing and intake is
not available. Also, over-the-counter (OTC) drug use is not
recorded in the databases. In all three countries, OTC NSAID
are available. OTC omeprazole (a PPI) is available in the UK
(for short-term use). In all three countries only prescription
NSAID and PPI are (partly) reimbursed. OTC NSAID and PPI
are therefore usually for short-term use, but an underestimation
of NSAID and PPI use in our study is conceivable. Low-dosed
H2RA are available OTC in all three countries, but it is unlikely
that patients use doses that are high enough to classify as
gastroprotection. Misclassification of the outcome was reduced
by manual/electronic validation of the records after sensitive
electronic searches based on both codes and key words in free
text. A sensitivity analysis that included only definite cases
strengthened the study findings. Heterogeneity was seen in
the incidence of UGI bleeding, whereas there was homogeneity
in the incidence of UGI events in the databases. The incidence
of UGI bleeding was substantially lower in Italy than in
The Netherlands and the UK. An explanation could be that the
most frequently used nsNSAID in Italy is nimesulide, a drug
that may lead to less UGI bleeding due to higher cyclooxygenase
2 specificity,28 and also variations in coding systems or health-
seeking behaviour may have contributed. The common case
definition is, however, that all outcomes were symptomatic
UGI events.
As a result of low numbers, the estimated risks differed
between databases, but the conclusions were consistent
across databases (data not shown) and heterogeneity was not
significant.
Protopathic bias would be introduced if patients start the
study drug (GPA) for the treatment of early symptoms of the
outcome of interest (UGI events). In this particular study, this is
an obvious threat to validity. Especially when GPA are started
later in the nsNSAID episode, the association between low GPA
adherence and UGI events would be overestimated. In order to
avoid protopathic bias, we defined the index date as the start of
symptoms leading to the diagnosis of the UGI event rather than
the date of diagnosis, whenever possible, and determined the
exposure before rather than at the index date.
Residual confounding might have been introduced by the H
pylori status of patients, on which we had no information. If
a positive H pylori status was to lead to a higher GPA adherence
and to a higher risk of UGI events, this would lead to an
underestimation of the true association between GPA adherence
and UGI events.
As a result of the fact that the databases contain prescription
data and no data on intake, we cannot make a distinction
between physician-induced or patient-induced non-adherence.
We calculated the risk associated with a suboptimal prescription
pattern, irrespective of the cause. Most likely both prescriber and
patient non-adherence play a role.
In conclusion, we observed a strong association between GPA
adherence and the risk of nsNSAID-related UGI events. The
results highlight the importance of GPA use during nsNSAID
therapy and suggest that an improvement in GPA adherence
could be beneficial in reducing the risk of nsNSAID-related UGI
events.
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